It is characterized by an earlier age of onset, greater metastatic potential, and poorer clinical outcomes than HR+ or HER2+ breast cancer [12, 13]; TNBC is treated primarily with chemotherapy, which is associated with higher toxicity and reduced HRQoL than endocrine therapy [14]. This evidence concerns the gene ERBB2 and breast carcinoma.